Cargando…

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Background: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult. Objective: This study was designed to develop a treatment tolerability index algorithm that combines AE reporti...

Descripción completa

Detalles Bibliográficos
Autores principales:	François, Clément, Guiraud-Diawara, Alice, Lançon, Christophe, Llorca, Pierre Michel, Hartry, Ann, Hammer-Helmich, Lene, Zighed, Djamel A., Tanasescu, Adrian, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645905/ https://www.ncbi.nlm.nih.gov/pubmed/29081922 http://dx.doi.org/10.1080/20016689.2017.1372026

Ejemplares similares

Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
por: Llorca, Pierre-Michel, et al.
Publicado: (2017)

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram
por: Llorca, Pierre-Michel, et al.
Publicado: (2015)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology
por: François, Clément, et al.
Publicado: (2017)

Lack of tolerable treatment options for patients with schizophrenia
por: Citrome, Leslie, et al.
Publicado: (2015)

The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
por: Lançon, Christophe, et al.
Publicado: (2008)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Burden of Medication Overuse in Migraine: A Cross-sectional, Population-Based Study in Five European Countries Using the 2020 National Health and Wellness Survey (NHWS)
por: Dissing, Agnete Skovlund, et al.
Publicado: (2023)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases
por: Touya, Maëlys, et al.
Publicado: (2019)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
por: Clay, Emilie, et al.
Publicado: (2019)

EGC Conferences
por: Guillet, Fabrice, et al.
Publicado: (2012)

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
por: Thokagevistk, Katia, et al.
Publicado: (2016)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

Results and validation of an index to measure health state of patients with depression in automated healthcare databases
por: Lamy, François-Xavier, et al.
Publicado: (2019)

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019)

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses
por: Thokagevistk, Katia, et al.
Publicado: (2019)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
por: Han, Ru, et al.
Publicado: (2019)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning
por: Ricciardi, Walter, et al.
Publicado: (2015)

Introduction
por: Toumi, Mondher, et al.
Publicado: (2015)

Economic and health implications from earlier detection of HIV infection in the United Kingdom
por: Zah, Vladimir, et al.
Publicado: (2016)

Non-profit drug research and development: the case study of Genethon
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Microbiota-Orientated Treatments for Major Depression and Schizophrenia
por: Fond, Guillaume B., et al.
Publicado: (2020)

Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study
por: Wang, Gang, et al.
Publicado: (2020)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
por: Sapin, Christophe, et al.
Publicado: (2016)

Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs
por: Moffa, Giusi, et al.
Publicado: (2023)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Social disparities in children’s exposure to second hand smoke at home: a repeated cross-sectional survey
por: Pisinger, Charlotta, et al.
Publicado: (2012)

Health service use among children with and without eczema, asthma, and hay fever
por: Hammer-Helmich, Lene, et al.
Publicado: (2016)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q5jakpd41j85f5qin4jgcqkm0c